Maimaitiyimin Dilinuer, Tao Yang, Shi Wenhui, Upur Halmurat, Aikemu Ainiwaer
Clin Lab. 2015;61(9):1213-9. doi: 10.7754/clin.lab.2015.141221.
The objective of this study was to determine if the clinical nitrate, Imdur, has a hepato-protective effect in chronic mountain sickness (CMS).
A total of 60 SD rats were included in the study. Fifty rats were used to model CMS and were randomly divided into the following groups (10 rats per group): 1) plateau, 2) nifedipine, 3) low dose imdur, 4) moderate dose imdur, and 5) high dose imdur. The remaining 10 rats were used for the control group. Thirty days after the CMS model was established, according to the appropriate body weight of the rats, intragastric administration of the treatment groups commenced. After 15 days, changes in pulmonary artery pressure (PAP) and pathology of liver tissues were observed. Homocysteine (Hcy), interleukin-6 (IL-6), C-reactive protein (CRP), superoxide dismutase (SOD), malondialdehyde (MDA) and glutathione peroxidase (GSH-PX) levels were also measured.
Compared with the control group, the levels of PAP, Hcy, IL-6, CRP, and MDA of the rats in the plateau model group, nifedipine group, and imdur groups were elevated. The levels of SOD and GSH-PX in these groups decreased relative to the control group. The injured rat livers were observed under the light microscope, revealing that hypoxia had caused tissue damage. Compared with that of the plateau model group, the levels of PAP, Hcy, IL-6, CRP, and MDA of the rats in the high dose imdur group were decreased (p < 0.05), and the levels of SOD and GSH-PX were increased (p < 0.05). Except for IL-6, the other parameters were comparable to normal values and better than those of the nifedipine group. Liver tissue from the high dose imdur group demonstrated less tissue damage from pathological sections.
High dose imdur has hepato-protective effects in CMS rat models.
本研究的目的是确定临床用硝酸盐药物依姆多（Imdur）在慢性高原病（CMS）中是否具有肝脏保护作用。
本研究共纳入60只SD大鼠。50只大鼠用于建立CMS模型，并随机分为以下几组（每组10只）：1）高原组，2）硝苯地平组，3）低剂量依姆多组，4）中剂量依姆多组，5）高剂量依姆多组。其余10只大鼠作为对照组。在CMS模型建立30天后，根据大鼠的适当体重，开始对治疗组进行灌胃给药。15天后，观察肺动脉压（PAP）变化及肝组织病理学变化。同时测定同型半胱氨酸（Hcy）、白细胞介素-6（IL-6）、C反应蛋白（CRP）、超氧化物歧化酶（SOD）、丙二醛（MDA）和谷胱甘肽过氧化物酶（GSH-PX）水平。
与对照组相比，高原模型组、硝苯地平组和依姆多组大鼠的PAP、Hcy、IL-6、CRP和MDA水平升高。这些组的SOD和GSH-PX水平相对于对照组降低。在光学显微镜下观察到大鼠肝脏受损，表明缺氧已导致组织损伤。与高原模型组相比，高剂量依姆多组大鼠的PAP、Hcy、IL-6、CRP和MDA水平降低（p<0.05），SOD和GSH-PX水平升高（p<0.05）。除IL-6外，其他参数与正常值相当且优于硝苯地平组。高剂量依姆多组肝组织病理切片显示组织损伤较小。
高剂量依姆多在CMS大鼠模型中具有肝脏保护作用。
